ORAMED PHARMACEUTICALS INC.
Close on Oct 19, 2026
- Market cap
- $172.56M
- P/E (TTM)
- 1.0
- Dividend yield
- 6.16%
About Oramed Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Oramed Pharmaceuticals Inc. is a pharmaceutical company that researches and develops oral delivery solutions for therapeutic proteins. Its proprietary Protein Oral Delivery technology enables oral formulations designed to protect active proteins, such as insulin, from gastrointestinal degradation and allow safe oral absorption without biological or chemical modification. In addition to internal development activities, the company allocates capital to strategic investments, royalty arrangements, and partnerships across healthcare, biotechnology, and life sciences businesses.
The company maintains its principal executive offices in New York, New York, and operates a wholly-owned subsidiary, Oramed Ltd. Its operational presence and business activities involve partnerships, clinical trial programs, and corporate agreements across the United States, Israel, and the British Virgin Islands.
Summary of the business section of Oramed Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ORAMED PHARMACEUTICALS INC.
- Founded
- 2002
- Headquarters
- New York, NY
- Address
- 1185 Avenue Of The Americas, 3rd Floor 10036
- Phone
- (646) 844-1164
- Website
- www.oramed.com
- Employees
- 13, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Kesselman & Kesselman C.P.A.s, Tel Aviv, Israel
Stock & identifiers
- Ticker
- ORMP
- Exchange
- Nasdaq
- Shares outstanding
- 42M, Aug 10, 2026
- Public float
- $77.66M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-12 reverse, Feb 28, 2013; 1-for-12 reverse, Jan 23, 2013
- SEC CIK
- 1176309
- CUSIP
- 68403P203
- ISIN
- US68403P2039
- LEI
- 5299006K52ZIIGQJ6R84
- EIN
- 98-0376008
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Miriam Kidron | Chief Scientific Officer, Director | 1,341,263 |
| Nadav Kidron | President and CEO, Director | 3,897,740 |
| Joshua Hexter | COO & CBO | 1,358,130 |
| Avraham Gabay | Chief Financial Officer | 881,076 |
| Yehuda Reznick | Director | 98,930 |
| Arie Mayer | Director | 168,009 |
| Benjamin Shapiro | Director | 2,023,220 |
| Daniel Aghion | Director | 107,191 |
| Leonard Sank | Director | 273,420 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr.Nadav Kidron | $4.77M | $4.80M | $2.02M | $118 | – |
| FY2024 Mr.Nadav Kidron | $2.10M | $2.14M | $1.28M | $105 | – |
| FY2023 Mr.Nadav Kidron | $1.66M | $265.81K | $918.94K | $19 | – |
| FY2022 Mr.Nadav Kidron | $6.83M | $7.45M | $2.17M | $84 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we have contracted with thirteen individuals for employment or consulting arrangements.”
Corporate history
Events identified from SEC filings